Skip to main content
. 2020 Sep 2;105(10):e3540–e3556. doi: 10.1210/clinem/dgaa489

Figure 2.

Figure 2.

Six-month placebo-controlled trial of teriparatide versus placebo. A.) Lumbar spine (LS) BMD; B.) Total hip (TH) BMD; C.) Femoral neck (FN) BMD; D.) Serum P1NP; E.) Serum osteocalcin (OCN); F.) Serum C-telopeptide (CTX); G.) Cancellous bone formation rate (Cn-BFR); H.) Endocortical BFR (Ec-BFR); and I.) Intracortical BFR (Ic-BFR). Placebo: Black bars; Teriparatide: Gray bars. * P < 0.05 for between-groups comparison.